Fwd: Former Director of CDC, Dr. Julie Gerberding Named President of Merck Vaccines

[Guest guest]

>Mon, 21 Dec 2009 21:23:47 -0500

>Former Director of CDC, Dr. Julie

>Gerberding Named President of Merck

> Vaccines

> Dannemann <ncowmail

> Dannemann <ncowmail

>

>I am speechless! This is unbelieveable.

>

>

>--- On Mon, 12/21/09, Jo Antonetti

><<joanneantonettijoanneantonetti wrote:

>

>Jo Antonetti

><<joanneantonettijoanneantonetti

>[PandemicFluOnlineList]: Dr. Julie

>Gerberding (of CDC) Named President of Merck Vaccines

> " pandemicflu online "

><<groupgroup

>Monday, December 21, 2009, 4:30 PM

>

>Ok people. Time to fashion our monkey wrenches,

>forged in truth, like never before.

>

>I could hardly read this article.....my oh my oh my.........

>

>

>

>Jo

>

>

>

>--- On Mon, 12/21/09, Sheri Nakken

><<vaccinedangersvaccinedangers wrote:

>

>

>SICK

>

>She got rewarded for her cooperation with drug

>companies while working for the CDC $$$$$$$$$$$$ $

>

><http://www.earthtimes.org/articles/show/dr-julie-gerberding-named-president-of\

-merck-vaccines,1098689.shtml>http://www.earthtim

>es.org/articles/ show/dr-julie- gerberding-

>named-president- of-merck- vaccines, 1098689.shtml

>

>Dr. Julie Gerberding (of CDC) Named President of Merck Vaccines

>

>WHITEHOUSE STATION, N.J. - (Business Wire) Merck

> & Co., Inc. (NYSE: MRK) today announced that Dr.

>Julie Gerberding has been named president of

>Merck Vaccines, effective January 25, 2010.

>

>Dr. Gerberding led the Centers for Disease

>Control and Prevention (CDC) as director from

>2002 to 2009. During her tenure at CDC, Dr.

>Gerberding led the agency during more than 40

>emergency response initiatives for health crises

>including anthrax bioterrorism, food-borne

>disease outbreaks, and natural disasters, and

>advised governments around the world on urgent

>public health issues such as SARS, AIDS, and obesity.

>

>

>“Vaccines are a cornerstone of Merck's

>commitment to health and wellness, " said Richard

>T. Clark, chairman and chief executive officer,

>Merck & Co., Inc. " We are delighted to welcome

>an expert of Dr. Gerberding's caliber to Merck.

>As a preeminent authority in public health,

>infectious diseases and vaccines, Dr. Gerberding

>is the ideal choice to lead Merck's engagement

>with organizations around the world that share

>our commitment to the use of vaccines to prevent disease and save lives. "

>

> " I’ve had the privilege in my previous work in

>academia and in the federal government to be a

>passionate advocate for public health priorities

>such as vaccines, which are an imperative

>component of global health development, " said

>Dr. Gerberding. " I am very excited to be joining

>Merck where I can help to expand access to vaccines around the world. "

>

>Dr. Gerberding will lead the company's $5

>billion global vaccine business. Merck currently

>markets a broad range of pediatric, adolescent

>and adult vaccines and is a leading provider of

>vaccines in countries around the world; in the

>U.S., Merck markets vaccines for 12 of the 17

>diseases for which the U.S. Advisory Committee

>for Immunization Practices currently recommends

>vaccines. She will be responsible for the

>commercialization of the current portfolio of

>vaccines, planning for the introduction of

>vaccines from the company's robust vaccine

>pipeline, and accelerating Merck's on-going

>efforts to broaden access to its vaccines in the

>developing world. Dr. Gerberding will also

>collaborate with leaders of Merck Manufacturing

>Division and Merck Research Laboratories to

>manage the critical linkages between basic

>research, late-stage development and

>manufacturing to expand Merck's vaccine offerings throughout the world.

>

>She received her undergraduate degree and her

>M.D. from Case Western Reserve University. Her

>internship, residency, and clinical pharmacology

>training were all at the University of

>California, San Francisco (UCSF), where she

>worked in a range of clinical, research and

>teaching roles prior to joining the CDC in 1998.

>Dr. Gerberding received her Masters of Public

>Health at the University of California, Berkeley.

>

>She is a member of the Institute of Medicine and

>a fellow of the Infectious Diseases Society of

>America and the American College of Physicians,

>and is board certified in Internal Medicine and

>Infectious Diseases. She is also a Clinical

>Professor of Infectious Diseases at Emory

>University and an Adjunct Associate Professor of

>Medicine in Infectious Diseases at UCSF.

>

>Dr. Gerberding has received more than 50 awards

>and honors, including the United States

>Department of Health and Human Services (DHHS)

>Distinguished Service Award for her leadership

>in responses to anthrax bioterrorism and the

>September 11, 2001 attacks. She was named to

>Forbes Magazine's 100 Most Powerful Women in the

>world in 2005, 2006, 2007, and 2008 and was

>named to TIME Magazine's 100 Most Influential People in the World in 2004.

>

>About Merck

>

>Today's Merck is working to help the world be

>well. Through our medicines, vaccines, biologic

>therapies, and consumer and animal products, we

>work with customers and operate in more than 140

>countries to deliver innovative health

>solutions. We also demonstrate our commitment to

>increasing access to healthcare through

>far-reaching programs that donate and deliver

>our products to the people who need them. Merck.

>Be Well. For more information, visit

><http://cts.businesswire.com/ct/CT?id=smartlink & url=http%3A%2F%2Fwww.merck.com & \

esheet=6125225 & lan=en_US & anchor=www.merck.com & index=1 & md5=0baff354554708b00d56d5\

3e2bdf6ffa>www.merck.com.

>

>

>Forward Looking Statement

>

>This news release includes “forward-looking

>statements” within the meaning of the safe

>harbor provisions of the United States Private

>Securities Litigation Reform Act of 1995. Such

>statements may include, but are not limited to,

>statements about the benefits of the merger

>between Merck and Schering-Plough, including

>future financial and operating results, the

>combined company’s plans, objectives,

>expectations and intentions and other statements

>that are not historical facts. Such statements

>are based upon the current beliefs and

>expectations of Merck’s management and are

>subject to significant risks and uncertainties.

>Actual results may differ from those set forth

>in the forward-looking statements.

>

>The following factors, among others, could cause

>actual results to differ from those set forth in

>the forward-looking statements: the possibility

>that the expected synergies from the merger of

>Merck and Schering-Plough will not be realized,

>or will not be realized within the expected time

>period, due to, among other things, the impact

>of pharmaceutical industry regulation and

>pending legislation that could affect the

>pharmaceutical industry; the risk that the

>businesses will not be integrated successfully;

>disruption from the merger making it more

>difficult to maintain business and operational

>relationships; Merck’s ability to accurately

>predict future market conditions; dependence on

>the effectiveness of Merck’s patents and other

>protections for innovative products; the risk of

>new and changing regulation and health policies

>in the U.S. and internationally and the exposure

>to litigation and/or regulatory actions.

>

>Merck undertakes no obligation to publicly

>update any forward-looking statement, whether as

>a result of new information, future events or

>otherwise. Additional factors that could cause

>results to differ materially from those

>described in the forward-looking statements can

>be found in Merck’s 2008 Annual Report on Form

>10-K, Schering-Plough’ s Quarterly Report on

>Form 10-Q for the quarterly period ended

>September 30, 2009, the proxy statement filed by

>Merck on June 25, 2009 and each company’s other

>filings with the Securities and Exchange

>Commission (SEC) available at the SEC’s Internet

>site:

><http://cts.businesswire.com/ct/CT?id=smartlink & url=http%3A%2F%2Fwww.sec.gov & es\

heet=6125225 & lan=en_US & anchor=www.sec.gov & index=2 & md5=cac1ae5cb5ea1a046abc66f05f\

26ed57>www.sec.gov.

>

>

>Merck & Co., Inc

>Media:

>Amy Rose, 908-423-6537

>Investor:

>Alex Kelly, 908-423-5185

>

>Sheri Nakken, R.N., MA, Hahnemannian Homeopath

>Vaccination Information & Choice Network, Washington State, USA

>Vaccines -

><http://www.nccn.net/%7Ewwithin/vaccine.htm>http://www.nccn.

>net/~wwithin/ vaccine.htm or

><http://www.wellwithin1.com/vaccine.htm>http://www.wellwith

>in1.com/vaccine. htm

>Vaccine Dangers, Childhood Disease Classes &

>Homeopathy Online/email courses - next classes start January 6 & 7

><http://www.wellwithin1.com/vaccineclass.htm>http://www.wellwith

>in1.com/vaccinec lass.htm or

><http://www.wellwithin1.com/homeo.htm>http://www.wellwith in1.com/homeo. htm

>

>

>

>

>

>

>--

>Regards,

>

> Dannemann

>Standing director, National Coalition of Organized Women (NCOW)

><http://www.ProgressiveConvergence.com>www.ProgressiveConvergence.com

>917 804-0786

>

>

>“It requires courage to utter truth; for the

>higher Truth lifts her voice, the louder will

>error scream, until its inarticulate sound is

>forever silenced in oblivion”…Mary Baker Eddy, Christian Science

>

> " Just Remember,

>when the weeding process takes place,

>you are the flowers. "

>

> - Charlie Lutes

>

>

>To be removed from list, please hit reply and say " remove " .